Digital solutions for the successful development of safe and effective active ingredients

The aim of M2Aind Drugs4Future is the development of a complex ICT-based technology platform for the multimodal analysis of tissues in 2D and 3D for faster, more standardized and more accurate prediction of the safety and effectiveness of pharmaceutical active ingredients in the process of pre-competitive development.

> 90% of all drug candidates in pharmaceutical research that are clinically tested on humans still fail. Obviously, the technologies that evaluate drug candidates preclinically are not predictive enough for the safety and effectiveness in sick people. M2Aind is therefore developing digital technologies that are intended to make a substantial contribution to reducing this “attrition rate”. 11 M2Aind partners are jointly exploring a new molecular high content drug profiling technology platform for faster, more standardized and more accurate prediction of the safety, pharmacokinetic-pharmacodynamics relationship and efficacy of active ingredients in earlier, less capital-intensive steps in pharmaceutical R&D. 

Platforms MS imaging, mid-infrared imaging, tissue clarification, 3D cell culture, live cell / 3D fluorescence microscopy from the development phase of the M2Aind innovation partnership are systematically expanded through the integration of further technologies in order to allow an even more comprehensive characterization of tissue treated with active substances: "trapped ion mobility spectrometry" (tims) MS imaging, 4D fluorescence microscopy with 4D perfusion analysis, Raman spectroscopy imaging, laser capture microdissection (3D) bioprinting, microfluidic 3D cell culture and localized chemical derivatization on tissues.

Diverse multimodal data types, namely morphological, molecular, hyperspectral-spectroscopic and functional data and data formats are integrated. The possibilities of data analysis are expanded through the use of machine learning with the main goal of identifying and interpreting complex biomarker signatures. The project is part of the pre-competitive, application-oriented research.


Prof. Dr. Rüdiger Rudolf

Institute for Molecular and Cell Biology


Industrial Partner

Improving human and animal health is the goal of the research-based pharmaceutical company Boehringer Ingelheim. The focus is on diseases for which there is currently no satisfactory treatment option. The company focuses on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for progressive prevention.


From biological diversity - the “toolbox of nature” - the company develops innovative solutions and products for successful applications in chemistry as well as in the cosmetics and food industries.


Bruker systems is the world market leader in mass spectrometric imaging and offers the largest range of scientific equipment and instruments in the world.


Cellzome GmbH is a biotechnology company that was founded in 2000 from the European Molecular Biology Laboratory (EMBL) in Heidelberg and taken over by GSK in May 2012. Cellzome is a leader in chemoproteomics.


The diagnostics SME, which operates in over 30 countries, develops and produces innovative detection methods for laboratory diagnostics and medical research.


The company is a global leader in healthcare, pharmaceuticals, life science and performance materials.



Development of novel materials for 3D cell cultivation.


Leica Microsystems is a leading global brand for innovative microscopy, camera and software solutions for imaging and analysis of macro, micro and nanostructures.


Development and manufacture of scientific instruments. Specialists for system solutions in liquid chromatography (LC). In addition, SunChrom GmbH has specialized in the development and optimization of front-end applications and sample preparation systems for MALDI and MALDI-MSI since 2003.


Sirius Fine Chemicals SiChem GmbH synthesizes active ingredients for the early phase / toxicology of drug development, mainly for the pharmaceutical industry. Our special focus is on the production of biologically and pharmacologically active compounds with increased bioavailability (prodrugs).